Crossmark

Romosozumab and cardiovascular safety—should we learn lessons from pioglitazone?

Crossref DOI link: https://doi.org/10.1007/s00198-021-06271-0

Published Online: 2022-02-18

Published Print: 2022-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jacob, Jubbin Jagan https://orcid.org/0000-0003-1755-5523
Paul, Thomas V. https://orcid.org/0000-0003-3315-341X
License Information

Text and Data Mining valid from 2022-02-18

Version of Record valid from 2022-02-18
More Information

Article History

Received: 2 December 2021

Accepted: 13 December 2021

First Online: 18 February 2022

Declarations

:

: None.